Sökning: WFRF:(Keech Anthony)
> (2008-2009) >
Long-term effects o...
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.
-
Hiukka, Anne (författare)
-
Westerbacka, Jukka (författare)
-
Leinonen, Eeva S (författare)
-
visa fler...
-
Watanabe, Hiroshi (författare)
-
- Wiklund, Olov, 1943 (författare)
- Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Wallenberg Laboratory,Institute of Medicine, Department of Molecular and Clinical Medicine
-
- Mattsson Hultén, Lillemor, 1951 (författare)
- Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Wallenberg Laboratory
-
Salonen, Jukka T (författare)
-
Tuomainen, Tomi-Pekka (författare)
-
Yki-Järvinen, Hannele (författare)
-
Keech, Anthony C (författare)
-
Taskinen, Marja-Riitta (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2008
- 2008
- Engelska.
-
Ingår i: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 52:25, s. 2190-7
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVES: The aim of this substudy was to ascertain whether long-term treatment with fenofibrate reduces surrogate measures of atherosclerosis, biomarkers of inflammation, and endothelial activation in patients with type 2 diabetes. BACKGROUND: Some fibrates may decrease cardiovascular events, improve endothelial function, and reduce levels of acute-phase proteins. In the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study, fenofibrate failed to decrease the primary end point of coronary events in patients with type 2 diabetes. METHODS: A total of 170 patients with type 2 diabetes of the FIELD Helsinki cohort were randomly assigned to micronized fenofibrate 200 mg/day or placebo in a double-blind design. Carotid intima-media thickness (IMT) and the augmentation index (a measure of large artery stiffness) were measured at baseline and at second- and fifth-year visits. Plasma levels of interleukin (IL)-6, C-reactive protein (CRP), serum amyloid A (SAA), secretory phospholipase A2 IIA (SPLA2), E-selectin, vascular cellular adhesion molecule (VCAM)-1, and intercellular adhesion molecule (CAM)-1 were determined by commercial enzyme-linked immunosorbent assay kits at the same visits. RESULTS: IMT and the augmentation index increased similarly in both treatment groups during the study. Plasma levels of CRP, IL-6, SPLA2, SAA, VCAM-1, ICAM-1, and E-selectin remained unchanged in both groups. CONCLUSIONS: Fenofibrate treatment was not associated with beneficial changes in IMT, augmentation index, or biomarkers of inflammation and endothelial function. (Fenofibrate Intervention and Event Lowering in Diabetes; NCT00132886).
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hiukka, Anne
-
Westerbacka, Juk ...
-
Leinonen, Eeva S
-
Watanabe, Hirosh ...
-
Wiklund, Olov, 1 ...
-
Mattsson Hultén, ...
-
visa fler...
-
Salonen, Jukka T
-
Tuomainen, Tomi- ...
-
Yki-Järvinen, Ha ...
-
Keech, Anthony C
-
Taskinen, Marja- ...
-
visa färre...
- Artiklar i publikationen
-
Journal of the A ...
- Av lärosätet
-
Göteborgs universitet